

A Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Effectiveness of Botanically Derived Inhibitors of 5- α -Reductase in the Treatment of Androgenetic Alopecia

NELSON PRAGER, Ph.D.,¹ KAREN BICKETT, R.N.,¹ NITA FRENCH, Ph.D.,²
and GENO MARCOVICI, Ph.D.³

ABSTRACT

Background: Androgenetic alopecia (AGA) is characterized by the structural miniaturization of androgen-sensitive hair follicles in susceptible individuals and is anatomically defined within a given pattern of the scalp. Biochemically, one contributing factor of this disorder is the conversion of testosterone (T) to dihydrotestosterone (DHT) via the enzyme 5- α reductase (5AR). This metabolism is also key to the onset and progression of benign prostatic hyperplasia (BPH). Furthermore, AGA has also been shown to be responsive to drugs and agents used to treat BPH. Of note, certain botanical compounds have previously demonstrated efficacy against BPH. Here, we report the first example of a placebo-controlled, double-blind study undertaken in order to examine the benefit of these botanical substances in the treatment of AGA.

Objectives: The goal of this study was to test botanically derived 5AR inhibitors, specifically the liposterolic extract of *Serenoa repens* (LSEsr) and β -sitosterol, in the treatment of AGA.

Subjects: Included in this study were males between the ages of 23 and 64 years of age, in good health, with mild to moderate AGA.

Results: The results of this pilot study showed a highly positive response to treatment. The blinded investigative staff assessment report showed that 60% of (6/10) study subjects dosed with the active study formulation were rated as improved at the final visit.

Conclusions: This study establishes the effectiveness of naturally occurring 5AR inhibitors against AGA for the first time, and justifies the expansion to larger trials.

INTRODUCTION

Androgenetic alopecia (AGA) shares a number of endocrinologic pathways with benign prostatic hyperplasia (BPH). Certain botanical compounds, and specifically those under investigation herein, have previously demonstrated the ability to inhibit key metabolic processes associated with BPH. Based on

the parallel etiologies of these two disorders, it was the central hypothesis of this pilot study to examine the putative benefit of botanicals in the treatment of AGA.

AGA is characterized by a receding hairline and/or hair loss within a specific pattern on the scalp (Shapiro et al., 2000). This condition, which affects men and women, is inherited as a polygenic disorder likely involving several

¹Clinical Research and Development Network, Aurora, CO.

²French and Associates, Atlanta, GA.

³Advanced Restoration Technologies, Denver, CO.

genes and multiple pathways, although the precise mechanism(s) remain unknown. However, one factor that has been demonstrated to contribute to the pathogenesis of this condition involves a genetically predetermined sensitivity to the effects of the androgenic hormone dihydrotestosterone, or DHT, in certain scalp hair follicles (Mowszowicz et al., 1993). DHT is believed to shorten the growth, or anagen, phase of the hair cycle, causing miniaturization of the follicles, and producing progressively finer hairs.

The production of DHT (reduced from testosterone [T]) is catalyzed by the enzyme 5- α reductase (5AR). In the prostate gland and in susceptible scalp hair follicles, androgen responsive cells express the genes encoding the steroid enzyme 5AR. 5AR is a membrane-bound enzyme that catalyzes the irreversible conversion of T to DHT (Itami et al., 1994). Two isozymes exist: the type 1 enzyme, encoded by the SRD5A1 gene, localized to chromosome 5p15, and the type 2 isozyme, encoded by the SRD5A2 gene localized to chromosome 2p23 (Morissette et al., 1996). Immunolocalization studies have shown that the type 1 enzyme is expressed primarily in newborn scalp, and in skin and liver, and the type 2 isozyme protein is expressed primarily in genital skin, liver, and the prostate (Negri-Cesi et al., 1999). In the prostate gland, the conversion of T to DHT by 5AR has been strongly implicated in the pathogenesis of BPH. Of note, the endocrine dysfunction associated with BPH bears a striking similarity to that linked to AGA.

BPH affects almost all men to some degree as they age, and can cause a significant disruption of lifestyle because of urinary outflow obstruction and irritative symptoms. BPH is characterized clinically by large, discrete nodules formed in the periurethral region of the prostate. These nodules may narrow the urethra sufficiently to cause full or partial obstruction. Increased conversion of T to its more active metabolite, DHT, has been shown to contribute to BPH, however, the specific etiology of BPH remains unknown. Nonetheless, studies have demonstrated that by blocking the conversion of T to DHT, with either pharmaceuticals or natural compounds, the circulating level of DHT is reduced by 80%, the size of the

prostate gland is reduced by approximately 20%, and the level of prostate-specific antigen (PSA) drops by approximately 50% (Mikolajczyk et al., 2000).

Interestingly, it has also been observed that eunuchs (males who have been castrated prior to the onset of puberty) do not develop BPH, nor do they develop AGA, and moreover, after castration BPH has been shown to regress (Wilson et al., 1999). Because normal testicular function appears to be necessary for the development of BPH, it is believed that the hyperplastic tissue metabolizes androgenic hormones differently than normal prostate tissue. Progressive growth of the prostate may cause significant obstruction of the urethra and interfere with the normal flow of urine (Wilt et al., 2000b). As with AGA, the incidence of BPH increases with advancing age. BPH is so common, that it is believed all men will develop BPH if they live long enough. Some degree of BPH is present in 80% of all men over 40 years old and this figure increases to 95% of men 80 years old (Guthrie and Siegel, 1999).

In support of a relationship between AGA and BPH, several lines of evidence have converged to support the view that circulating T and the modifying enzyme, 5AR, have profound effects on androgen metabolism, and provide insight into the role of these hormones in hair loss. Specifically, the absence of circulating T and, therefore, its metabolite DHT, in males castrated prior to puberty has been shown to prevent AGA in later life. These findings demonstrate the importance of this metabolism in the pathogenesis of male pattern hair loss (Giltay and Gooren, 2000).

Of equal relevance, it has been observed that in a group of male pseudohermaphrodites with inherited mutations in the 5AR gene, the preservation of the juvenile hairline invariably occurs (Imperato-McGinley et al., 1990). These examples demonstrate that whether the disturbance in androgen metabolism results from either the absence of substrate (T), the active metabolite DHT, or dysfunction of the enzyme 5AR, at least one phenotypic consequence is consistent and reproducible: terminal hair density as well as juvenile hairlines remain intact in such individuals.

In contrast, a third and critical observation has been noted in bodybuilders who self-administer anabolic steroids, in that excessive levels of circulating T and therefore DHT had the opposite effect of the first two examples, that of acceleration of hair loss in genetically susceptible individuals because of upregulation of the hormonal processes that result in AGA (Lise et al., 1999).

Collectively, these lines of evidence point to a common theme among disorders resulting from dysregulation of the conversion of T to DHT, and have led to the central hypothesis of this research. Until now, the only treatments available for AGA have consisted essentially of the topically administered drug Rogaine™ (minoxidil, 2% and 5%; Upjohn-Pharmacia, Kalamazoo, MI) and the orally delivered pharmaceutical Propecia™ (finasteride, 1 mg; Merck, Rahway, NJ).

Rogaine (topically applied minoxidil, 2%–5%) is the best-known drug in the category of medical AGA treatment. Minoxidil delivered via oral ingestion was initially indicated in the treatment of refractory hypertension. It was noted to cause hypertrichosis (increased non-sexual hair growth), however, the mechanism by which it stimulates hair growth remains unknown. Clinical trials have shown that a 2% solution applied topically to the scalp can stimulate hair growth in some men and women (Rushton et al., 1989).

Finasteride 1 mg (Propecia) was approved by the U.S. Food and Drug Administration (FDA) December 1997 for the treatment of male pattern hair loss (AGA) in men only. Safety and efficacy were demonstrated in men between 18 and 41 years of age with mild to moderate hair loss of the vertex and anterior midscalp area. Efficacy in bitemporal recession has not been established (Kaplan and Olsson, 1996). Propecia is not approved for use in women or children. Finasteride is a preferential, competitive inhibitor of the intracellular, type 2, 5AR isoenzyme that converts T into DHT, the more potent androgen. In target organs, finasteride treatment is thought to result in selective androgen deprivation, affecting DHT without lowering circulating levels of testosterone, thus preserving the desired androgen-mediated effects on muscle strength,

bone density, and sexual function. As noted above, the balding scalp in AGA contains miniaturized hair follicles and increased amounts of DHT compared to nonbalding scalp, and finasteride treatment inhibit the isozyme, resulting in a rapid reduction in scalp and serum DHT concentrations.

Because AGA shares similar hormonal pathways with BPH, it was previously recognized that the pharmaceutical agents useful against BPH may offer some potential benefit in the treatment of AGA. The modification of Proscar™ (finasteride, 5 mg; Merck; initially indicated for BPH), to Propecia (finasteride, 1 mg, new indication, AGA) serves as a paradigm for this rationale (Kaufmann, 1999). Similar to finasteride, several botanically derived substances have also demonstrated the ability to inhibit key hormonal processes associated with BPH. Importantly, these botanicals have not been linked with the spectrum of negative side-effects, adverse reactions, or teratogenicity associated with the pharmaceutically derived alternatives (Klepser and Klepser, 1999).

Recently, several clinical trials have reported the efficacy of botanical compounds in the treatment of a number of androgen-dependent conditions, and specifically, BPH. For example, among 1098 BPH patients tested in one recent study, the general safety profile of the lipsterolic extract of *Serenoa repens* (LSESr, 320 mg/d), or saw palmetto berry extract, compared favorably to that of finasteride, and sexual side-effects were less common with the extract than with the drug. In particular, the use of this extract has not been associated with erectile dysfunction, ejaculatory disturbance, or altered libido (Wilt et al., 2000a). Remarkably, in another biochemical study, it was found that LSESr was a threefold more effective inhibitor than finasteride (5 mg/d) at concentrations adjusted to the recommended doses for BPH treatment. It should be noted that finasteride as indicated for AGA is dosed significantly lower (1 mg/d), suggesting, a 15-fold more potent level of inhibition at the recommended daily dose of LSESr (320 mg/d) (Delos et al., 1994).

LSESr is the first line of BPH treatment in Europe and elsewhere, and is believed to act by

inhibiting 5AR. Several *in vitro* experiments in cultured human foreskin fibroblasts have found LSESr to be a strong and specific inhibitor of the enzyme 5AR (Swoboda and Kopp, 1999). *In vitro* studies have also shown that LSESr inhibits both isozymes, whereas finasteride selectively inhibits only type 2 5AR (Iehle et al., 1995). Moreover, finasteride demonstrates a solely competitive inhibition, while LSESr has additionally been found to display noncompetitive as well as uncompetitive inhibition of the type 1 as well as type 2 5AR isozyme (Gerber, 2000).

As with LSESr, the primary indication for treatment with the plant phytosterol β -sitosterol has been in the treatment of BPH. In addition to a potential role in 5AR inhibition, as a minor component of LSESr, β -sitosterol in particular has been shown to lower the bioavailability of cholesterol in the local environment in animal models, thereby suggesting it may inhibit downstream steroid hormone biosynthesis, specifically testosterone (Wang and Ng, 1999). One potential mechanism of action of β -sitosterol in the prostate and the hair follicle, therefore, may involve a local reduction of T (substrate) in the microenvironment of 5AR active tissues.

In one large clinical study, a total of 519 men undertook a 26-week double-blind controlled study testing β -sitosterol against placebo in assessing urinary flow as the operative criterion. Compared with placebo, β -sitosterol significantly improved urinary symptom scores and flow measures (Bracher, 1997). Based on the success of β -sitosterol in the treatment of BPH, as well as other factors, it was incorporated as an active component of the AGA trial study formulation. In recognition of the efficacy that these botanically derived 5AR inhibitors demonstrated in the treatment of BPH, it was the central hypothesis of this study to test them for the first time against AGA.

SUBJECTS AND METHODS

Patient population

Included in this study were males between 23 and 64 years of age, in good health, with

mild-to-moderate AGA. Exclusion criteria consisted of (1) those who had been on prescription or over-the-counter treatment for AGA or a prostate condition within the past 30 days prior to initiation of the trial; (2) symptomatic cardiac problems, uncontrolled hypertension, symptomatic hypotension, autoimmune disorders; (3) those who had participated in a clinical trial within 30 days prior to enrollment; (4) those with any known allergy to any ingredients in the test products; and (5) those with any other medical condition that could interfere with successful conclusion of the study. Subjects enrolled in this study met guidelines established under the Hamilton/Norwood scale of hair loss. Study subjects presented with moderate to significant male pattern hair loss in the vertex area (grade II vertex through grade VI vertex). Baseline characteristics of study subjects were reasonably well matched and fell within the desired study protocol inclusion parameters. The protocol was approved by the Western Institutional Review Board, Olympia, WA, and all investigations were performed following written informed consent in accordance with these guidelines. All investigative staff members participating in this study were trained to evaluate and report the parameters described in the study protocol.

Study protocol

After informed consent, approximately 26 male subjects ages 23 to 64 with AGA were initially evaluated and randomly assigned, in a double-blind manner, to one of the following groups: either active oral softgel supplement, 1 softgel twice daily or matching oral placebo, 1 softgel twice daily.

The composition of the softgels, a Good Manufacturing Practices-compliant product manufactured by Softgel Technologies Inc., Los Angeles, California, encased in an inert carob-colored soluble shell, was as follows. The active softgel components consisted of β -sitosterol, 50 mg, and saw palmetto extract (standardized to 85%–95% liposterolic content) 200mg. Systemic absorption of the active softgel components' bioavailability was enhanced by the use of lecithin, 50 mg; inositol, 100 mg; phosphatidyl

BOTANICALS IN THE TREATMENT OF AGA

choline, 25 mg; niacin, 15 mg; biotin, 100 μ g. The historic experience of other investigators testing these botanicals against BPH was an important factor in determination of the recommended drug-dosage levels for this study.

Historically, a number of animal studies support the safety, efficacy, and dosage for these botanical agents (Schilcher, 1999); however, no animal research was undertaken as a part of this proof-of-concept trial. The placebo soft gels, encased in an inert carob colored soluble shell, were composed as follows: soybean oil, 540 mg.

Test product and placebo were prepared by Softgel Technologies Inc. to be identical in appearance. Product was randomly assigned code numbers. Codes were not available to involved personnel until after completion of the trial and final data review. Study participation encompassed a duration of approximately 4.6 months, with a maximum duration of approximately 5.4 months. There were three scheduled clinic visits: baseline/randomization (approximately week 0), enrollment (approximately week 0), and conclusion (approximately week 21). The enrollment visit (visit 1) was also the randomization visit. During this visit subjects were randomized, study medication was dispensed, and baseline investigative staff evaluations were made. The block size for this study was 30 with a treatment versus control ratio of 1:1. All subjects were instructed to use Neutro-

gena™ T/Gel (Los Angeles, CA) or similar shampoo to standardize any variable that might otherwise occur by the use of differing shampoo formulations.

Written informed consent was obtained from all study subjects prior to entry, with a copy given to each subject. A brief medical history was obtained including vital signs (weight, blood pressure, heart rate). Overall hair assessment was made using a standardized scale (Table 1).

Subjects were asked to rate their current level of satisfaction with their hair. Subjects were then assigned to treatment in sequential order and given instructions regarding study agent. Study supplies were then dispensed and subjects were sent home to begin the study.

Study completion

As with the enrollment visit, a brief medical history was obtained including vital signs (weight, blood pressure, heart rate). Overall hair assessment was made using a standardized seven-point scale (Table 1). Subjects were asked to evaluate any change with respect to their current level of satisfaction with their hair.

Efficacy measures

Efficacy measures were administered at baseline, and final visit. These were: (1) investigative staff assessed hair growth (Fig. 1) and

TABLE 1. SUBJECT SELF-ASSESSMENT QUESTIONS AND RATING OF SUBJECT CURRENT SATISFACTION

Self Assessment Questions

1. **Since the start of the study, I can see my bald spot getting smaller.** Choice of answers: strongly agree, agree, no opinion either way, disagree, strongly disagree.
2. **Because of the treatment I have received since the start of the study, the appearance of my hair is:** Choice of answers: a lot better, somewhat better, a little better, same, a little worse, somewhat worse, a lot worse.
3. **Since the start of the study, how would you describe the growth of your hair?** Choice of answers: greatly increased, moderately increased, slightly increased, no change, slightly decreased, moderately decreased, greatly decreased.
4. **Since the start of the study, how effective do you think the treatment has been in slowing your hair loss?** Choice of answers: very effective, somewhat effective, not very effective, not effective at all.
5. **Compared to the beginning of the study, which statement best describes your satisfaction with the appearance of:** (1) The hairline at the front of your head? (2) The hair on top of your head? (3) Your hair overall? Choice of answers: very satisfied, satisfied, neutral, dissatisfied, very dissatisfied.

Subject Current Satisfaction

1. **What is your current level of satisfaction with your hair condition?** Choice of answers: -3 very dissatisfied, -2 moderately dissatisfied, -1 slightly dissatisfied, +1 slightly satisfied, +2 moderately satisfied, +3 very satisfied.




FIG. 1. Graphic representation of the results of the Investigative Staff Assessment of the study group. The upper bar represents subjects treated with active formulation, versus the lower bar representing subjects in the placebo group. The x-axis represents numbers of subjects (1–10). The results demonstrated that 6 of 10 subjects (60%) were rated as improved in the group taking the active formulation, compared to 1 of 9 subjects (11%) in the placebo control group.

(2) patient self-assessment of treatment efficacy and satisfaction with appearance (Fig. 2).

Patient self-assessment

The parameters assessed by study subjects in this analysis were the following questions: size of bald spot; appearance of hair; growth of hair; rate of hair loss; and satisfaction with appearance of hair (Table 1).

Investigative staff assessment

As recorded in the Study Protocol Case Report Forms, the primary measure utilized by the investigative staff in determination of formulation efficacy was a seven point scale starting with (–3) denoting greatly decreased hair density, ranging to (+3) marking greatly increased hair density (Table 2).

Toxicity and adverse events

Risk of toxicity in this study was considered minimal inasmuch as the median lethal dose (LD₅₀) for the botanicals under investigation was far greater than the highest dosages likely to be consumed. Numerous independent BPH studies evaluating similar formulations support this observation (Carraro et al., 1996; Gerber et al., 1998; Wilt et al., 1998, 1999, 2000a).

Adverse events were recorded in the Study Protocol Case Report Form Manual per Insti-

tutional Review Board (IRB) guidelines. The causality of adverse events was based on a four-point scale with 1 = great probability that the adverse event was likely to be related to use of the study drug and 4 = great probability that the adverse event was not likely to be related to use of the study drug.

The adverse events noted during the course of this study included nausea, constipation, and diarrhea. However, no adverse events occurring within this pilot study were determined as likely to be related to the use of the active compound. The data are presented in accordance with the CONSORT clinical study reporting guidelines as described by Moher et al. (2001).

RESULTS

Study goals

Our primary goal in this initial pilot study was to assess if the study formulation was efficacious in arresting scalp hair loss as well as improving hair quality. Based on anecdotal and open-label data, we anticipated being able to show a positive trend demonstrating a response to therapy. The two measurements utilized for this purpose were:

1. Investigative staff assessment using a standard assessment format




FIG. 2. Graphic representation of the results of the subjects' self-assessment of the study group. The criterion represented here was the perceived deterioration of the bald spot. The left-hand bar represents subjects in the treatment group, versus the right-hand bar representing subjects in the placebo group. The y-axis represents percent deterioration. The results demonstrated that 0 of 10 subjects (0%) in the group taking active formulation reported any deterioration of the bald spot, compared to 3 of 9 subjects (33%) in the placebo control group.

Twenty-six (26) male subjects, ages 23 to 64 were enrolled in the trial between July 1999 and October 1999. Of these 26, 19 completed the trial. Seven dropped out prior to study completion; two of these because of a perceived adverse event (Table 3). Five of the seven patients who withdrew did not report an adverse event, but dropped out for reasons unrelated to the research study. A total of 19 patients were evaluated after study completion. Duration of participation in this study ranged from 18 to 24.7 weeks.

On the basis of the investigative staff assessment of change in the patient's scalp hair growth from baseline (Fig. 1), treatment with the active study formula demonstrated 60% (6/10) subjects rated as "improved" at the final visit as compared to baseline. In contrast, only 11% (1/9) in the placebo group were rated as "improved." These findings show a markedly positive response to treatment as denoted by the proportion of responders. Because of the small sample size, statistical significance and/or confidence intervals were not endpoint goals of this pilot study ($n = 19$) nor were they achieved; however, future large-scale studies will be designed with these definable endpoints in mind.

2. Subject self-assessment of hair condition

The study participant's self-assessment criterion reflected a time-dependent analysis of any change noted in the thinning areas of the scalp. Subject assessment of the "appearance of the bald spot" at the final visit compared to baseline were as follows. In the treatment group [0], 0% deteriorated versus the placebo group where [3] 33% deteriorated (Fig. 2).

DISCUSSION

As previously noted, both LSESr and β -sitos-terol represent, among other indications, first-line BPH treatments in Europe and elsewhere. This is meaningful in light of the previously noted etiologic similarities between BPH and AGA. However, to the best of our knowledge, prior to the small trial described in this study, no controlled and blinded clinical research had previously been conducted on a formula, either oral or topical, combining LSESr and β -sitos-terol, in the treatment of AGA.

The composition under discussion was designed on the basis of the excellent safety and efficacy previously demonstrated by each component alone. However, the published studies were performed on each substance tested separately, but never together. Nonetheless, both LSESr and β -sitosterol alone have established clinical efficacy against BPH.

For example, in a meta-analysis of 18 randomized controlled trials comparing LSESr to finasteride, involving 2939 men, both magnitude of improvement and confidence interval, all tend to favor the efficacy of LSESr with less erectile dysfunction that that associated with finas-

TABLE 2. INVESTIGATOR RATING SCALE FOR SUBJECT ASSESSMENT IN THE COURSE OF THIS STUDY

Assessment	Score
Greatly decreased	-3
Moderately decreased	-2
Slightly decreased	-1
No change	0
Slightly increased	+1
Moderately increased	+2
Greatly increased	+3

TABLE 3. PERCEIVED ADVERSE EVENTS ARISING IN THE COURSE OF THE STUDY

Complaint	Placebo (n = 9)	Treatment (n = 10)	Resolved during study	Relationship to treatment
Skin	0	1	No	Not related
GI	0	1 loss of appetite	No	Possible
		1 flatulence	Yes	Unlikely
		1 diarrhea	Yes	Unlikely
Neurologic	1	0	Yes	Placebo
GU	1 frequent urination	0	No	Placebo
Miscellaneous	1 aware of heart beat	0	No	Placebo
	1 heightened sensations			

In total, there were eight perceived adverse events reported by seven subjects in the course of this study. One subject in the treatment group reported acne that was present at baseline and worsened during the course of the study. Three subjects in the treatment group reported GI symptoms, including loss of appetite, flatulence, and diarrhea. One subject in the placebo group reported lightheadedness with a bowel movement. One subject in the placebo group reported frequent urination, and one subject in the placebo group reported heightened sensations and awareness of heartbeat.

GI, gastrointestinal; GU, genitourinary.

teride (Millon et al., 1999). Also, in a randomized, double-blind trial, BPH patients treated with β -sitosterol showed a significant improvement in lower tract urinary symptoms as compared to placebo recipients (Wilt et al., 1998).

Furthermore, a 26-week LSESr versus finasteride trial involved 1098 men led to a remarkable finding that highlights an important safety aspect of these two therapies. It was found that finasteride lowers the level of prostate-specific antigen (PSA) by 30% to 50%. This test is routinely used to screen for prostate cancer and monitor prostate cancer therapy (Gerber et al., 1998). This study showed that although finasteride does not affect the sequelae of prostate cancer, it may complicate the diagnostic process, because PSA values must be approximately doubled. In the same study, however, LSESr demonstrated no impact on PSA levels, suggesting the absence of this potentially dangerous side-effect.

Moreover, in contrast to phytotherapy, where negative side-effects are virtually nonexistent, finasteride has been implicated with the following adverse reactions; decreased libido (1.8%), erectile dysfunction (1.3%), and ejaculation disorder (1.2%) (Carraro et al., 1996). Resolution did occur in all men who discontinued therapy with finasteride because of these side-effects. Finally, finasteride treatment is contraindicated in females as a result of its teratogenic potential. In fact, even the handling of crushed finasteride tablets by pregnant females is discouraged because of the possibility of sys-

temic absorption, which may result in risk of feminizing birth defect to a male fetus (Wolf and Kunte, 1999).

In contrast, these warnings and contraindications have never been associated with the botanically based substances tested in this study, and in fact LSESr has been safely and widely used in women for the treatment of dysmenorrhea, genital/urinary problems, and difficulty associated with lactation (Lee et al., 2000). In recognition of the safe and potentially efficacious nature of the substances under examination, this small proof of principle trial was conducted with the goal of demonstrating a positive response for the active formula as measured against placebo.

In summary, Investigative Staff Assessment showed that 60% (6/10) subjects were rated as "improved" by the investigator at the final visit compared to baseline. This compares to 11% (1/9) in the placebo group (Fig. 1). Furthermore, the subject assessment analysis of the appearance of the bald spot at the final visit compared to baseline showed that in the treatment group, no subjects deteriorated. In contrast, the placebo group reported three subjects as deteriorated. Inasmuch as maintenance of hair density and hair quality is a goal for many patients, this finding is in itself noteworthy. Based on the small number of subjects ($n = 19$) our data justify the design of a larger scale study of these substances in the treatment of AGA.

In conclusion, we have observed objective evidence of efficacy using orally administered

botanical therapy in the treatment of AGA, for the first time. The implementation of larger gender-specific clinical trials, incorporating local delivery concomitant with oral administration is planned as an appropriate next step. Research is also underway to identify additional botanical compounds that may offer useful activity against AGA.

REFERENCES

- Bracher F. Phytotherapy of benign prostatic hyperplasia. *Urologe A* 1997;36:10-17.
- Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. *Prostate* 1996;29:231-240.
- Delos S, Iehle C, Martin PM, Raynaud J. Inhibition of the activity of "basic" alpha-reductase (Type 1) detected in DU 145 cells and expressed in insect cells. *Steroid Biochem Molec Biol* 1994;48:347-352.
- Gerber G. What is saw palmetto used for, and does it interact with any medications? *Health News* 2000;6:10.
- Gerber GS, Zagaja GP, Bales GT, Chodak GW, Contreras BA. Saw palmetto (*Serenoa repens*) in men with lower urinary tract symptoms: Effects on urodynamic parameters and voiding symptoms. *Urology* 1998;51:1003-1007.
- Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. *Clin Endocrinol Metab* 2000;85:2913-2921.
- Guthrie RM, Siegel RL. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: The Hypertension and BPH Intervention. *Trial Clin Ther* 1999;21:1732-1748.
- Iehle C, Delos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5 alpha-reductase isoforms—A comparative study of selective inhibitors. *J Steroid Biochem Mol Biol* 1995;54:273-279.
- Imperato-McGinley J, Shackleton C, Orlic S, Stoner E. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor: Comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. *J Clin Endocrinol Metab* 1990;70:777-782.
- Itami S, Sonoda T, Kurata S, Takayasu S. Mechanism of action of androgen in hair follicles. *J Dermatol Sci* 1994;7:98-103.
- Kaplan SA, Olsson CA. Patient satisfaction with finasteride in the treatment of symptomatic benign prostatic hyperplasia. *Clin Ther* 1996;18:73-83.
- Kaufman KD. Finasteride, 1 mg (Propecia), is the optimal dose for the treatment of men with male pattern hair loss. *Arch Dermatol* 1999;135:989-990.
- Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. *Am J Health Syst Pharm* 1999;56:125-138.
- Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D. Alternative therapies used by women with breast cancer in four ethnic populations. *J Natl Cancer Inst* 2000;92:42-47.
- Lise ML, da Gama e Silva TS, Ferigolo M, Barros HM. Abuse of anabolic-androgenic steroids in sports. *Rev Assoc Med Bras* 1999;45:364-370.
- Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, Wheeler TM, Slawin KM. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. *Urology* 2000;55:41-45.
- Millon R, Jacqmin D, Muller D, Guillot J, Eber M, Abecassis J. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: Clinical implications. *Eur Urol* 1999;36:278-285.
- Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet* 2001;357:1191-1194.
- Morissette J, Durocher F, Leblanc JF, Normand T, Labrie F, Simard J. Genetic linkage mapping of the human steroid 5 alpha-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23 → p22. *Cytogenet Cell Genet* 1996;73:304-307.
- Mowszowicz I, Melanitou E, Doukani A, Wright F, Kuttent F, Mauvais-Jarvis P. Androgen binding capacity and 5 alpha-reductase activity in pubic skin fibroblasts from hirsute patients. *J Clin Endocrinol Metab* 1993;56:1209-1213.
- Negri-Cesi P, Colciago A, Poletti A, Motta M. 5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3. *Prostate* 1999;41:224-232.
- Rushton DH, Unger WP, Cotterill PC, Kingsley P, James KC. Quantitative assessment of 2% topical minoxidil in the treatment of male pattern baldness. *Clin Exp Dermatol* 1989;14:40-46.
- Shapiro J, Wiseman M, Lui H. Practical management of hair loss. *Can Fam Phys* 2000;46:1469-1477.
- Schilcher H. Is there a rational therapy for symptomatic treatment of benign prostatic hyperplasia with phyto-genic drugs? Illustrated with the example of the prostate agent from *Serenoa repens*. *Wien Med Wochenschr* 1999;149:236-240.
- Swoboda H, Kopp B. *Serenoa repens*—The saw palmetto or dwarf palm. *Wien Med Wochenschr* 1999;149:235.
- Wang HX, Ng TB. Natural products with hypoglycemic, hypotensive, hypocholesterolemic, antiatherosclerotic and antithrombotic activities. *Life Sci* 1999;65:2663-2677.
- Wilson JD, Roehrborn C. Long-term consequences of castration in men: Lessons from the Skoptzy and the eu-

- nuchs of the Chinese and Ottoman courts. *J Clin Endocrinol Metab* 1999;84:4324-4331.
- Wilt T, Ishani A, Stark G, MacDonald R, Mulrow C, Lau J. *Serenoa repens* for benign prostatic hyperplasia. *Cochrane Database Syst Rev* 2000a;2:CD001423.
- Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. *Cochrane Database Syst Rev* 2000b;2:CD001042.
- Wilt TJ, MacDonald R, Ishani A. Beta-sitosterol for the treatment of benign prostatic hyperplasia. *BJU Int* 1999;83:976-983.
- Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review. *JAMA* 1998;280:1604-1609.
- Wolff H, Kunte C. Therapy of androgenetic alopecia with finasteride. What must be considered in consultation and drug prescribing. *MMW Fortschr Med* 1999;141:38-40.

Address reprint requests to:

Geno Marcovici, Ph.D.

1211 S. Parker Road, Suite 100

Denver, CO 80231

E-mail: dr.marcovici@hairgenesis.com